Grifois, S.A.
Symbol: GRFS (NASDAQ)
Company Description:
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
- Today's Open: $10.09
- Today's High: $10.359
- Today's Low: $9.946
- Today's Volume: 702.56K
- Yesterday Close: $9.97
- Yesterday High: $10.09
- Yesterday Low: $9.88
- Yesterday Volume: 531.86K
- Last Min Volume: 50
- Last Min High: $9.99
- Last Min Low: $9.99
- Last Min VWAP: $9.99
- Name: Grifois, S.A.
- Website: https://www.grifols.com
- Listed Date: 2011-06-02
- Location: ,
- Market Status: Active
- CIK Number: 0001438569
- SIC Code:
- SIC description:
- Market Cap: $6.78B
- Round Lot: 100
- Outstanding Shares: 680.51M
- Asset Type: ADRC
Filing Date | Filing Type | Format |
---|---|---|
2025-09-29 | 6-K | View |
2025-07-30 | 6-K | View |
2025-07-29 | 6-K | View |
2025-07-29 | 6-K | View |
2025-06-12 | 6-K | View |
2025-06-05 | 6-K | View |
2025-05-12 | 6-K | View |
2025-05-06 | 6-K | View |
2025-05-02 | 6-K | View |
2025-04-11 | 20-F | View |
2025-04-09 | SCHEDULE 13G/A | View |
2025-04-02 | 6-K | View |
2025-03-31 | 6-K | View |
2025-03-10 | 6-K | View |
2025-02-27 | 6-K | View |
2025-02-26 | 6-K | View |
2025-02-26 | 6-K | View |
2025-02-25 | 6-K | View |
2025-02-14 | SCHEDULE 13G | View |
2024-12-23 | 6-K | View |